- Home
- SRV vs PROF Comparison
SRV vs PROF Comparison
Compare SRV & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.2M | 238.1M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SRV | PROF |
|---|---|---|
| Price | $45.10 | $6.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 57.3K | ★ 100.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $4.99 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $37.70 | $3.92 |
| 52 Week High | $46.43 | $8.95 |
Technical Indicators
Market Signals| Indicator | SRV | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 54.08 |
| Support Level | $42.01 | $5.75 |
| Resistance Level | $46.24 | $7.07 |
| Average True Range (ATR) | 0.88 | 0.42 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 88.68 | 65.83 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.